Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
Letter From the Yale CBIT Director: Advancing Collaboration and Breakthroughs in Healthcare Innovation
Starting Your Journey in Public Health Innovation: Dr. Leslie Asanga, PharmD, MB 09/27/2024 12:00PM—1:00PM